Correspondence 0001193125-24-206283 from OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715) (OKUR)
OnKure Therapeutics, Inc. (OKUR) (CIK 0001637715)
Date: Aug. 23, 2024 · CIK: 0001637715 · Accession: 0001193125-24-206283
AI Filing Summary & Sentiment
File numbers found in text: 333-280369
Letter
RENEO PHARMACEUTICALS, INC.
18575 Jamboree Road, Suite 275-S
Irvine, CA 92612
August 23,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Gary Newberry
Lynn Dicker
Tyler Howes
Tim Buchmiller
Re: Reneo Pharmaceuticals, Inc.
Registration Statement on Form S-4 (File No. 333-280369)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Reneo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern Time on August 26, 2024, or as soon thereafter as practicable.
The Company requests that it be notified of such effectiveness by a telephone call to either Bradley C. Brasser of Jones Day at (612) 217-8886 or Jonn R. Beeson of Jones Day at (949) 553-7528. Thank you for your attention to this matter.
cc: Bradley C. Brasser, Jones Day
Jonn R. Beeson, Jones Day
Sincerely,
Reneo Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612 August 23, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Gary Newberry Lynn Dicker Tyler Howes Tim Buchmiller Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-4 (File No. 333-280369) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Reneo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern Time on August 26, 2024, or as soon thereafter as practicable. The Company requests that it be notified of such effectiveness by a telephone call to either Bradley C. Brasser of Jones Day at (612) 217-8886 or Jonn R. Beeson of Jones Day at (949) 553-7528. Thank you for your attention to this matter. cc: Bradley C. Brasser, Jones Day Jonn R. Beeson, Jones Day Sincerely, Reneo Pharmaceuticals, Inc. /s/ Gregory J. Flesher Gregory J. Flesher President and Chief Executive Officer